GlassScriptPhysician profile
Dennis A Burachinsky
NPI 1427376698
$2,996.29
in general payments reported to CMS, 2019-2025
25 companies · $604 in 2025
The $604 reported for 2025 was more than what a typical Otolaryngology/Facial Plastic Surgery provider received nationally (typical 2025 total: $305).
See the full distribution for Otolaryngology/Facial Plastic Surgery
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $470 · 2020: $80.35 · 2021: $69.96 · 2022: $213 · 2023: $910 · 2024: $649 · 2025: $604.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,010 · Education: $152.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,010.42 |
| Education | $151.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $738.95 | 2019-2025 | |
| Optinose US, INC. | $540.28 | 2019-2024 | |
| Regeneron Healthcare Solutions, INC. | $308.73 | 2019-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $229.82 | 2019-2025 | Cuvitru |
| Aerin Medical INC. | $202.70 | 2022-2024 | |
| Glaxosmithkline, LLC. | $172.97 | 2019-2025 | Nucala, Arexvy |
| Sanofi-Aventis U.S. LLC | $151.98 | 2023-2025 | |
| Stryker Corporation | $107.18 | 2019 | |
| Csl Behring | $89.23 | 2019-2025 | Haegarda, Hizentra |
| Alk-Abello, INC | $81.88 | 2019-2025 | Odactra, Ragwitek, Grastek |
| Novartis Pharmaceuticals Corporation | $75.21 | 2019-2023 | |
| Kaleo, INC. | $43.24 | 2019-2023 | Auvi-Q |
| Ars Pharmaceuticals Operations, INC. | $33.55 | 2025 | Neffy |
| Incyte Corporation | $29.36 | 2024 | Opzelura |
| Phathom Pharmaceuticals, INC. | $24.53 | 2025 | Voquezna |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $21.26 | 2024 | Ebglyss |
| Smith+Nephew, INC. | $21.05 | 2019 | |
| Arbor Pharmaceuticals, INC. | $20.56 | 2019 | |
| Acclarent, INC | $17.78 | 2019 | |
| Grifols USA, LLC | $17.34 | 2025 | Xembify |
| Medtronic, INC. | $16.47 | 2021 | |
| Hikma Pharmaceuticals USA | $15.55 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $14.95 | 2022 | |
| Olympus America INC. | $12.72 | 2019 | |
| Glenmark Therapeutics INC. | $9.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dennis Burachinsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.